{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aglatimagene+besadenovec",
    "query": {
      "intervention": "Aglatimagene besadenovec"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aglatimagene+besadenovec&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T10:53:48.280Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03131037",
      "title": "Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "CAN-2409 + valacyclovir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-05-04",
      "completion_date": "2023-09-20",
      "has_results": false,
      "last_update_posted_date": "2025-07-11",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03131037"
    },
    {
      "nct_id": "NCT01436968",
      "title": "Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Aglatimagene besadenovec + valacyclovir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo + valacyclovir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 711,
      "start_date": "2011-09",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 72,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Multiple Locations, Arizona + 56 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Multiple Locations",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436968"
    },
    {
      "nct_id": "NCT00634231",
      "title": "A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Recurrent Ependymoma"
      ],
      "interventions": [
        {
          "name": "AdV-tk",
          "type": "BIOLOGICAL"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 8,
      "start_date": "2010-10",
      "completion_date": "2021-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634231"
    },
    {
      "nct_id": "NCT02446093",
      "title": "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Borderline Resectable Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Aglatimagene besadenovec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemoradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stereotactic body radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2015-10",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 2,
      "location_summary": "Fort Myers, Florida • Columbus, Ohio",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02446093"
    },
    {
      "nct_id": "NCT00638612",
      "title": "AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "AdV-tk",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2008-08",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 3,
      "location_summary": "Duarte, California • La Jolla, California • Columbus, Ohio",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00638612"
    },
    {
      "nct_id": "NCT00589875",
      "title": "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma",
        "High Grade Glioma"
      ],
      "interventions": [
        {
          "name": "CAN-2409",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2007-03",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589875"
    },
    {
      "nct_id": "NCT01997190",
      "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Pleural Effusion",
        "Lung Cancer",
        "Mesothelioma",
        "Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "AdV-tk + valacyclovir",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2013-10",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01997190"
    },
    {
      "nct_id": "NCT03576612",
      "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "AdV-tk",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-02-27",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576612"
    },
    {
      "nct_id": "NCT02768363",
      "title": "Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "aglatimagene besadenovec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "valacyclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 187,
      "start_date": "2016-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 22,
      "location_summary": "Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more",
      "locations": [
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02768363"
    },
    {
      "nct_id": "NCT07332000",
      "title": "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer Patients Treated by Radiotherapy",
        "Prostate Cancer (Adenocarcinoma)"
      ],
      "interventions": [
        {
          "name": "aglatimagene besadenovec + valacyclovir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy (EBRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "Candel Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2025-10-30",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-30T10:53:48.280Z",
      "location_count": 7,
      "location_summary": "Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07332000"
    }
  ]
}